KMT2A and cancer: The unique dependence of MLL1 activity on WDR5 may be of therapeutic relevance, as we and others have shown that pharmacological targeting of the MLL interaction site on WDR5 can functionally antagonize MLL1 in cancers that are dependent on MLL1 activity (38–40).